Patents Assigned to Otsuka Pharmaceuticals Co., Ltd.
  • Pharmaceutical compounds
    Patent number: 11466016
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 11, 2022
    Assignees: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Christopher Norbert Johnson, Ildiko Maria Buck, Gianni Chessari, James Edward Harvey Day, Hideto Fujiwara, Christopher Charles Frederick Hamlett, Steven Douglas Hiscock, Rhian Sara Holvey, Steven Howard, John Walter Liebeschuetz, Nicholas John Palmer, Jeffrey David St Denis, David Geoffrey Twigg, Andrew James Woodhead
  • In-body power source having high surface area electrode
    Patent number: 11464423
    Abstract: Power sources that enable in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body power sources of the invention include a solid support, a first high surface area electrode and a second electrode. Embodiments of the in-power sources are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the power sources of the invention.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: October 11, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hooman Hafezi, Timothy Robertson, Eric Snyder, Brad Cozad
  • MEDICAL TABLET, AND MANUFACTURING METHOD AND MANUFACTURING APPARATUS FOR MEDICAL TABLET
    Publication number: 20220313602
    Abstract: An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and is held in a state of being positioned above pharmaceutical powder filled in a die hole before compression. The IC chip is supplied by a pusher.
    Type: Application
    Filed: June 15, 2022
    Publication date: October 6, 2022
    Applicants: Otsuka Pharmaceutical Co., Ltd., Omori Machinery Co., LTD.
    Inventors: Etsuhiro MAEDA, Yasutoshi KOHATA
  • INJECTABLE FORMULATION
    Publication number: 20220305007
    Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
    Type: Application
    Filed: February 11, 2022
    Publication date: September 29, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
  • SYSTEM FOR SUPPLY CHAIN MANAGEMENT
    Publication number: 20220311474
    Abstract: A system for tracking a product from origin to destination is disclosed. The system includes a probe that comprises two plates, a power source and a processor. The power source is controlled by the processor to produce an oscillating output at the plates. Using the oscillating voltage, the probe interrogates a device through capacitive coupling. The device includes a control unit, a memory unit, and first and second materials physically associated with the device for communication using capacitive coupling. Information associated with the device is transferred from the device to the probe through capacitive coupling between the first and second materials and the first and second plates, respectively.
    Type: Application
    Filed: January 18, 2022
    Publication date: September 29, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Mark J. Zdeblick
  • Inositol phosphate-containing composition
    Patent number: 11446317
    Abstract: The present invention further provides a composition for inhibiting purine body absorption, a composition for inhibiting purine nucleotide metabolism, a composition for inhibiting phosphatase, a composition for inhibiting uric acid level elevation, a composition for improving blood pressure, a composition for improving blood glucose level, a composition for improving liver function, a composition for controlling serum iron level, or a composition for promoting calcium absorption, comprising an inositol phosphate or a salt thereof. The present invention further provides a composition comprising an inositol phosphate or a salt thereof, wherein the taste thereof is improved by adding thereto a predetermined amount of calcium lactate.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: September 20, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Ikenaga, Hiroki Noguchi, Chieko Kohashi, Noriyuki Kouda, Ayako Takaishi
  • COMMUNICATION SYSTEM WITH ENHANCED PARTIAL POWER SOURCE AND METHOD OF MANUFACTURING SAME
    Publication number: 20220280061
    Abstract: The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can also measure the conditions of the environment surrounding the system.
    Type: Application
    Filed: December 14, 2021
    Publication date: September 8, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Jeremy FRANK, Peter BJELETICH, Hooman HAFEZI, Robert AZEVEDO, Robert DUCK, Iliya PESIC, Benedict COSTELLO, Eric SNYDER
  • ORAL PHARMACEUTICAL COMPOSITION
    Publication number: 20220280418
    Abstract: Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Motoyasu YOSHIMURA, Takuya FUJII, Naoki KAMADA, Ryohei TOGASHI, Ryuta AONO, Xinyu WANG
  • ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20220273647
    Abstract: Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 1, 2022
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Motoyasu YOSHIMURA, Takuya FUJII, Naoki KAMADA, Ryohei TOGASHI, Ryuta AONO, Xinyu WANG
  • OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
    Publication number: 20220265613
    Abstract: The present invention provides an oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(?O)— wherein Y1 is a group such as —C(?O)—, A1 is a group such as a tower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
    Type: Application
    Filed: February 24, 2022
    Publication date: August 25, 2022
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Minoru OKADA, Masaya Kato, Norifumi Sato, Tetsuyuki Uno, Hideki Kitagaki, Junpei Haruta, Hidetaka Hiyama, Tomonori Shibata
  • Oxazole compound crystal
    Patent number: 11414391
    Abstract: Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles 2?(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuK? characteristic X-rays.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: August 16, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Naohiko Kanai, Takayuki Yasutomi, Ryosuke Hirota
  • Gel-like food composition
    Patent number: 11412770
    Abstract: Provided is a novel gel-like food composition. The gel-like food composition contains 0.1 to 10 wt % of a free branched-chain amino acid, 1 to 12 wt % of a protein, and 104/g to 1014/g of a probiotic.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 16, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Keiko Toyooka, Koichiro Hamada, Hiroshi Saitoh
  • BENZOAZEPINE COMPOUND-CONTAINING FREEZE-DRIED COMPOSITION
    Publication number: 20220249523
    Abstract: A formulation stably comprising a tolvaptan prodrug is provided. Specifically, a freeze-dried composition comprising a compound represented by Formula (1): or a metal salt thereof and a disaccharide is provided.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 11, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takakuni MATSUDA, Nobutomo SAKO
  • Detection chip, detection system, and detection method
    Patent number: 11408817
    Abstract: The detection system according to the present invention has a detection chip, a light source, and a detection unit. The detection chip has a housing that has an opening at an upper portion, and a reaction field for trapping a substance to be detected, the reaction field being arranged on an inner surface of the side walls included in the housing. The light source irradiates the detection chip with light from the outside such that evanescent light or surface plasmon resonance is generated under the reaction field. The detection unit detects light which is emitted from the detection chip when the light source irradiates the detection chip with light, and the amount of which changes depending on the amount of the substance to be detected trapped in the reaction field.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: August 9, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tomonori Kaneko, Kosuke Nagae, Takatoshi Kaya, Yukito Nakamura
  • DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE
    Publication number: 20220241293
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 4, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki Aihara, Shizuo Kinoshita
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 11400087
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: August 2, 2022
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • EDIBLE ADHESIVES AND INGESTIBLE COMPOSITIONS INCLUDING THE SAME
    Publication number: 20220232873
    Abstract: Edible adhesives and ingestible compositions that include the same are provided. Aspects further include methods of making and using the compositions.
    Type: Application
    Filed: February 14, 2022
    Publication date: July 28, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kevin Cheng, Patricia Johnson, Raymond Schmidt, Anuj Patel
  • Measuring device, measurement abnormality detecting method, and program
    Patent number: 11397150
    Abstract: Presently disclosed is a way to provide a measuring device capable of easily detecting measurement abnormality without increasing load in hardware. The measuring device may include: an emission means that may emit light to a measurement target region; a light measurement means that may measure light output from the measurement target region by emission with the emission means; a driving means that may move a position of at least one of the measurement target region and the emission means; and a determination means that may compare measurement values of the light measured a plurality of times by the light measurement means while changing positions of the measurement target region by the driving means and thereby determines abnormality of a measurement result.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: July 26, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Youichi Aoki, Tetsuya Noda
  • HIGH VISCOSITY O/W EMULSION COMPOSITION CONTAINING ADENOSINE PHOSPHATE
    Publication number: 20220211590
    Abstract: The present disclosure provides an O/W emulsion composition, comprising an adenosine phosphate and/or a salt thereof; an acrylic acid-alkyl, methacrylate copolymer; an oil content; and water; and comprising a water-soluble polymer selected from a swelling thickener, an associative thickener, a polysaccharide and a derivative thereof, and a mixture thereof, and/or a pH adjuster which is an organic alkali compound; wherein the composition has a viscosity of equal to or higher than 10,000 mPa·s.
    Type: Application
    Filed: April 24, 2020
    Publication date: July 7, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Miyoko OGIHARA, Momoko SUMA, Shiori MIYAWAKI
  • ADENOSINE PHOSPHATE-CONTAINING O/W TYPE EMULSION COMPOSITION HAVING LOW VISCOSITY
    Publication number: 20220202684
    Abstract: The present disclosure provides an O/W emulsion composition, comprising an adenosine phosphate and/or a salt thereof; an acrylic acid-alkyl methacrylate copolymer; an oil content; and water; and comprising a water-soluble polymer selected from a swelling thickener, an associative thickener, a polysaccharide and a derivative thereof and a mixture thereof, and/or a pH adjuster which is an organic alkali compound; wherein the composition has a viscosity of less than 10,000 mPa·s.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 30, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Miyoko OGIHARA, Momoko SUMA, Shiori MIYAWAKI